Voltron Therapeutics, Inc.’s Scientific Co-Founder Dr. Mark C. Poznansky has Guest Essay Published in the New York Times
July 20, 2021 09:00 ET
|
Voltron Therapeutics, Inc.
NEW YORK, July 20, 2021 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced that a the Company’s Scientific Co-Founder, Dr. Mark C. Poznansky’s guest essay titled “The Vaccines We Have...
Voltron Therapeutics, Inc. Announces COVID-19 and Pandemic Preparedness Presentation to Congressional Offices and Agencies, Including HHS, NIH, FDA, and DoD
April 13, 2021 08:00 ET
|
Voltron Therapeutics, Inc.
NEW YORK, April 13, 2021 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced that the Company presented to Congressional Offices and Agencies, including HHS, NIH, FDA and the DoD on...
Voltron Therapeutics, Inc. Announces Positive Data from Animal Testing of Self-Assembling Vaccine in the Fight Against COVID-19
March 24, 2021 08:00 ET
|
Voltron Therapeutics, Inc.
NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced positive data from its second set of preclinical animal testing of its HaloVax™ Self-Assembling Vaccine (SAV)...
Voltron Therapeutics, Inc. Initiates Additional Animal Testing of Self-Assembling Vaccine in Fight Against COVID-19
February 09, 2021 08:00 ET
|
Voltron Therapeutics, Inc.
NEW YORK, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. announced today it has initiated its second set of preclinical animal testing of its HaloVax™ Self-Assembling Vaccine (SAV)...
Laidlaw Venture Partners Portfolio Company Voltron Therapeutics, Inc. Names Anthony Zook, Former CEO of AstraZeneca North America, Executive Chairman
January 28, 2021 09:15 ET
|
Voltron Therapeutics, Inc.
NEW YORK, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced that it has appointed life science veteran Anthony Zook Executive Chairman of its Board of Directors. As a...
Voltron Therapeutics, Inc. to Participate in the 2020 Fall Defense TechConnect Virtual Innovation Summit
November 16, 2020 11:30 ET
|
Voltron Therapeutics, Inc.
NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced that it will participate in the 2020 Fall TechConnect Virtual Innovation Conferences' Virtual Defense...
Voltron Therapeutics, Inc. Executes Manufacturing Agreement with Global Pharmaceutical Contract Development and Manufacturing Organization
September 16, 2020 09:40 ET
|
Voltron Therapeutics, Inc.
NEW YORK, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced that it has executed a manufacturing agreement for its vaccine portfolio with a global pharmaceutical contract...
Voltron Therapeutics, Inc. Announces Completion of First Small Animal Safety and Immunogenicity Study Assessing the Effect of Novel COVID-19 Vaccine, HaloVax™
September 15, 2020 08:30 ET
|
Voltron Therapeutics, Inc.
NEW YORK, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. announced today the successful completion of its previously announced first small animal safety and immunogenicity study...
Voltron Therapeutics Retains Buenaventura Advisors, LLC to Explore Strategic Alternatives for its HaloVax™ Subsidiary
July 09, 2020 09:25 ET
|
Voltron Therapeutics, Inc.
NEW YORK , July 09, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. (the Company) announced today it has retained Buenaventura Advisors, LLC to explore strategic alternatives for HaloVax, a...
Voltron Therapeutics, Inc. Initiates Animal Testing of Self-Assembling Vaccine in Fight Against COVID-19
July 08, 2020 08:30 ET
|
Voltron Therapeutics, Inc.
NEW YORK, July 08, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. announced today it has initiated preclinical animal testing of the first construct of its HaloVax Self-Assembling Vaccine (SAV)...